Remarkably, ibrutinib does not inhibit the growth and survival of BCR wild-type tumors with MyD88- and/or CARD11 mutations [235, 239, 240] indicating that ibrutinib specifically targets ABC-DLBCL tumors that rely on chronic active BCR signaling [235]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.